HomeComparePCHI vs MRK

PCHI vs MRK: Dividend Comparison 2026

PCHI yields 7.02% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $25.9K in total portfolio value· pulled ahead in Year 4
10 years
PCHI
PCHI
● Live price
7.02%
Share price
$24.47
Annual div
$1.72
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.8K
Annual income
$1,095.98
Full PCHI calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — PCHI vs MRK

📍 MRK pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPCHIMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PCHI + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PCHI pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PCHI
Annual income on $10K today (after 15% tax)
$596.56/yr
After 10yr DRIP, annual income (after tax)
$931.58/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MRK beats the other by $7,665.13/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PCHI + MRK for your $10,000?

PCHI: 50%MRK: 50%
100% MRK50/50100% PCHI
Portfolio after 10yr
$44.8K
Annual income
$5,604.88/yr
Blended yield
12.52%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

PCHI
No analyst data
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PCHI buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPCHIMRK
Forward yield7.02%2.81%
Annual dividend / share$1.72$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$31.8K$57.7K
Annual income after 10y$1,095.98$10,113.78
Total dividends collected$9.0K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PCHI vs MRK ($10,000, DRIP)

YearPCHI PortfolioPCHI Income/yrMRK PortfolioMRK Income/yrGap
1$11,402$701.83$11,213$373.04+$189.00PCHI
2$12,948$747.87$12,667$512.06+$281.00PCHI
3$14,648$793.71$14,439$708.14+$209.00PCHI
4← crossover$16,512$839.19$16,640$988.16$128.00MRK
5$18,552$884.12$19,432$1,394.07$880.00MRK
6$20,779$928.36$23,057$1,992.90$2.3KMRK
7$23,206$971.78$27,889$2,894.79$4.7KMRK
8$25,844$1,014.25$34,518$4,286.29$8.7KMRK
9$28,709$1,055.68$43,912$6,494.35$15.2KMRK
10$31,815$1,095.98$57,714$10,113.78$25.9KMRK

PCHI vs MRK: Complete Analysis 2026

PCHIStock

PCHI provides segmented exposure to the North American fixed income market with the intention to exceed the performance of the broader high yield market over a credit cycle. It aims to deliver overall total return through investments in fixed- and floating-rate high yield debt securities of middle market issuers in the US and, partially, in Canada. These below investment-grade securities may be corporate bonds, senior loans, convertible bonds, and preferred stock that are believed to be undervalued. The fund utilizes value investing with the intention of balancing the risks with the potential reward of discounted securities. It mainly follows a bottom-up investment approach, emphasizing downside protection, with the aim of adding value initially through security selection. The fund will not focus on maturity and duration but expects to hold securities with shorter maturity and duration than broad-based high yield market indices. The portfolio will typically include 60 to 150 bonds.

Full PCHI Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this PCHI vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PCHI vs SCHDPCHI vs JEPIPCHI vs OPCHI vs KOPCHI vs MAINPCHI vs JNJPCHI vs ABBVPCHI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.